|Participating centres||UMC Utrecht|
A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multi-center study in patients with Amyotrophic Lateral Sclerosis (ALS).
This study is to assess the effect of levosimendan versus placebo on respiratory function in patients with ALS.
Overall enrolment: 450 patients
Centres: 34 sites in the US, 5 sites in Australia, 7 sites in Canada, 2 sites in Austria, 3 sites in Belgium, 3 sites in Finland, 5 sites in Germany, 1 site in Italy, 5 sites in Spain, 3 sites in Sweden, 1 site in Ireland, 3 sites in The United Kingdom and 2 sites in The Netherlands (UMCU and AMC)Read more on clinicaltrialsregister.eu Read more on clinicaltrials.gov